Our Phone — +7 (495) 710-68-44




New web-site for Longevica Pharmaceuticals with a teaser for perspective co-investors

In March 2014, Longevica Pharmaceuticals started fundraising campaign to create drugs based on eEF2-kinase. Teaser can be found at newly created web-site. 

Longevica Pharmaceuticals, a biotech start-up established in 2008 by Dr. Alexey Ryazanov, is focused on developing novel chemical inhibitors of eukaryotic elongation factor 2 kinase (eEF2K), a highly promising drug target whose inhibition can achieve multiple beneficial effects ranging from suppressing tumor growth to protecting normal cells from the cytotoxicity of chemotherapeutic agents. 

Rostock Group owns 51% of Longevica Pharmaceuticals.

Topic: Longevica Pharmaceuticals

© 2009 “Rostock Group”
8/3, Pokryshkina str, Moscow, Russian Federation


Tel./Fax: +7 (495) 710-68-44
E-mail: info@grostock.ru
Web Production: 25 Кadr Advertising Agency